Latest Earnings Results: Q3 '26
Estimated EPS
-$0.20
Reported EPS
-$0.24
Surprise
-21.21%
Estimated Rev
$24.03M
Reported Rev
$24.27M
Surprise
+0.98%
• Reported GAAP EPS of -$0.24 up 20.00% YoY • Reported revenue of $24.27M up 24.72% YoY • SOPHiA GENETICS expects FY 2026 revenue at the upper end of its previously issued $94M to $96M range and adjusted EBITDA loss between $29M and $32M.
Bullish Takeaway
SOPHiA GENETICS expanded analysis volume and its genomics customer base, added new BioPharma collaborations and companion-diagnostic programs, and reduced adjusted EBITDA loss while reaffirming a 2027 profitability target.
Bearish Takeaway
SOPHiA GENETICS reported lower gross-margin comparisons, warned sustained foreign-exchange movements could weigh on fourth-quarter revenue, and disclosed litigation expenses tied to Guardant Health lawsuits that may increase.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.17 | -- | -- | N/A |
Q3 '26 | -$0.20 | -$0.24 | -21.21% | MISSED |
Q2 '26 | -$0.21 | -$0.30 | -42.83% | MISSED |
Q1 '26 | -$0.23 | -$0.27 | -16.13% | MISSED |
Q4 '25 | -$0.24 | -$0.28 | -17.89% | MISSED |